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Iron polymaltose complex (IPC) oﬀers similar eﬃcacy with superior tolerability to ferrous sulfate in adults, but randomized trials
in children are rare. In a prospective, open-label, 4-month study, 103 children aged >6 months with iron deﬁciency anemia (IDA)
were randomized to IPC once daily or ferrous sulfate twice daily, (both 5mg iron/kg/day). Mean increases in Hb to months 1 and 4
withIPCwere1.2±0.9g/dL and 2.3±1.3g/dL, respectively, (both P = 0.001 versus baseline) and 1.8±1.7g/dL and 3.0±2.3g/dL
with ferrous sulfate (both P = 0.001 versus baseline) (n.s. between groups). Gastrointestinal adverse events occurred in 26.9% and
50.9% of IPC and ferrous sulfate patients, respectively (P = 0.012). Mean acceptability score at month 4 was superior with IPC
versus ferrous sulfate (1.63 ± 0.56 versus 2.14 ± 0.75, P = 0.001). Eﬃcacy was comparable with IPC and ferrous sulfate over a
four-month period in children with IDA, but IPC was associated with fewer gastrointestinal adverse events and better treatment
acceptability.
1.Introduction
Iron deﬁciency (ID) aﬀects an estimated two billion people
worldwide [1] and is one of the most common nutrient
deﬁciencies in all regions, including Europe [2, 3]. If no
corrective action is taken, ID can manifest as iron deﬁciency
anemia (IDA), which has been linked to fatigue, weakened
immunity, poor work performance, and a decreased quality
of life [4]. Moreover, infants with IDA have been shown
to achieve lower scores on mental and motor development
tests than infants with normal iron status [5]. Inadequate
intestinal absorption of nutritional iron to meet physiolog-
ical requirements may occur due to inadequate iron intake,
increased iron requirement (e.g., during periods of rapid
growth), or chronic blood loss. Infants, preschool children,
and adolescents are among the groups most susceptible to
development of IDA [6].
Providing adequate iron supplementation, ideally before
the development of anemia, can prevent the systemic neuro-
logical and developmental disorders that result from IDA in
infancy and childhood [5]. Long-term oral iron is frequently
used as a ﬁrst-line therapy, but iron salts such as ferrous
sulfateareassociatedwithahighincidenceofgastrointestinal
side eﬀects such as nausea, vomiting, constipation, and
diarrhea [7]. Polynuclear preparations based on the ferric
form of iron, such as iron hydroxide polymaltose complex
(IPC), have been developed to improve tolerability. IPC
provides similar iron bioavailability to ferrous sulfate [8]
but has a stable structure that confers more controlled
absorption of iron [9]. A recent meta-analysis [10]h a s
conﬁrmed that IPC and ferrous sulfate provide similar
improvements in hemoglobin (Hb) levels in adult patients
with iron deﬁciency anemia, but with superior tolerability.
The available data comparing IPC versus ferrous sulfate
in children suggest that eﬃcacy is similar with the two
preparations [10], but randomized trials are more rare than
in adults and long-term data are lacking. Two randomized
studies, one in 30 iron deﬁcient children with or without
anemia aged 24–81 months [11] and the other in 49 children
with IDA aged 6–40 months [12], reported no diﬀerence
between IPC and ferrous sulfate for the improvement in Hb
or other eﬃcacy markers over a two-month period, although2 International Journal of Pediatrics
one trial observed a more rapid improvement in Hb with
ferrous sulfate. Tolerability was superior with IPC in both
studies [11, 12].
The current study evaluated the eﬃcacy, tolerability, and
acceptability of IPC and ferrous sulfate in a cohort of 103
pediatric patients with IDA during a four-month treatment
period.
2. Methods
2.1. Study Design. This was a prospective, randomized,
open-label, four-month study undertaken in children with
IDA at the Department of Pediatric Health and Diseases
Outpatient Clinics of the University of Istanbul during 2009.
Patients were eligible for enrollment if they were older than
six months of age and presented with at least one of the
symptoms of fatigue, faintness, or getting tired quickly,
without known underlying chronic disease. Diagnosis of
IDA was based on age-dependent lower limits of normal for
Hb and iron status parameters (Table 1)[ 13, 14]. Patients
with Hb values below normal were tested for transferrin
saturation (TSAT), serum iron, and serum ferritin levels. If
any of these iron parameters were below normal, the patient
was included in the trial and randomized to iron treatment
with ferrous sulfate (twice daily; Ferro Sanol Syrup, Adeka,
Turkey) or IPC (once daily; Ferrum Hausmann Syrup,
Abdi Ibrahim, Turkey) at a total dose of 5mg iron/kg/day.
Randomization was performed by alternating treatment
allocation of newly recruited patients on a weekly basis,
that is, patients who were recruited during one week were
allocated to one treatment group and those recruited during
the following week to the other treatment group.
The study was conducted in accordance with the Decla-
ration of Helsinki and Good Clinical Practiceguidelines. The
study protocol was approved by the local Ethics Committee
(registration number 2009/1897) and legal representatives of
thechildrenprovidedinformedconsentbeforeenrollmentin
the study.
2.2. Laboratory Evaluation. Baseline measurements com-
prised the erythrocyte-related hematologic markers Hb,
hematocrit (Hct), mean corpuscular volume (MCV), mean
corpuscular hemoglobin (MCH), mean corpuscular hemo-
globin concentration (MCHC), and red blood cell (RBC)
count as well as the iron status markers serum iron, serum
iron binding capacity (SIBC), TSAT, and serum ferritin.
Outcome assessments comprised the percentage of reticulo-
cytes at day 7, erythrocyte markers at months 1 and 4, and
iron status markers at month 4. Erythrocyte markers and
reticulocytes were measured with an ABX Pentra DX 120
Analyzer. Iron parameters were assessed with standard lab-
oratory methods using COBAS INTEGRA 800 and COBAS
Ea u t o a n a l y z e r s .
2.3. Tolerability and Acceptability. Gastrointestinal adverse
events with a possible relation to study medication (e.g.,
nausea, abdominal pain, diarrhea, and constipation) that
developed during the course of treatment and were reported
at any study visit. Treatment acceptability was assessed using
the Wong-Baker scale, which scores facial expressions on a
scale of 0–5 points that reﬂect diﬃculties during adminis-
t r a t i o no fi r o nt r e a t m e n t[ 15]. A “happy face” (0) stands for
no diﬃculties, while a “sad face” (5) indicates that the child
refused or was forced to take the medicine.
2.4. Statistical Analyses. Data are presented as mean ±
standard deviation (SD) unless otherwise stated. Statistical
analyses were performed with the NCSD (Number Cruncher
Statistical System) 2007 and PASD 2008 Statistical Software
(Utah, USA). Student’s t-test was used for group comparison
of parameters with normal distribution. Mann-Whitney U
test was used for group comparison of parameters that did
not show normal distribution. Variance analysis was used for
the detection of diﬀerence between repeated measurements
of parameters showing normal distribution. Wilcoxon test
wasusedforrepeatedmeasureanalysisofparametersthatdid
notshownormaldistribution.Signiﬁcancewasconsideredat
the level of P<0.05.
3. Results
3.1. Patient Population. One hundred and three children
were screened for eligibility, all of whom met the criteria for
inclusion and were recruited to the study (42 girls, 61 boys;
mean age 6.4 ± 5.1 years, range 7 months to 17 years). The
patients were evenly distributed between the two treatment
groups (IPC, n = 52, 49.5%; ferrous sulfate, n = 51,
50.5%). Baseline characteristics were comparable between
both groups except for serum ferritin levels, which were
signiﬁcantly higher in patients randomized to IPC compared
to ferrous sulfate (Table 2). However, baseline ferritin levels
were below the age-dependent lower limit of normal in both
groups.
3.2. Eﬃcacy. The percentage of reticulocytes at day 7 was
similar with IPC (1.41 ± 1.31%) and ferrous sulfate
(1.57 ± 1.29%; P = 0.905). All erythrocyte-related hemato-
logic parameters at months 1 and 4 and all iron parameters
at month 4 showed a signiﬁcant improvement from baseline
with both treatments (Table 2). A signiﬁcant improvement
in Hb was observed by month 1 in the IPC group (9.5 ±
1.1g/dLto10.6 ±1.0g/dL,P = 0.001)andtheferroussulfate
group (9.4 ± 1.6g/dL to 11.2 ± 0.9g/dL, P = 0.001), with
an increase of more than 2g/dL in both treatment arms by
month4(IPC11.7 ±0.8g/dL,ferroussulfate12.4 ±1.0g/dL;
both P = 0.001 versus baseline). The changes in Hb and Hct
levels from baseline to months 1 and 4 were not signiﬁcantly
diﬀerent between treatment groups, although at month 1
there was a nonsigniﬁcant trend to a greater increase in Hb
in the ferrous sulfate group (IPC 1.2 ± 0.9g/dL versus 1.8
± 1.7g/dL, P = 0.060). In terms of iron status parameters,
TSAT improved from approximately 5% in each group at
baseline to >20% at month 4 (IPC 5.1 ± 3.3% to 20.2 ±
15.5%, P = 0.001; ferrous sulfate 5.4 ± 3.5% to 22.4 ±
13.2%, P = 0.001) with no signiﬁcant diﬀerence between the
groups. The increase in serum ferritin level from baseline toInternational Journal of Pediatrics 3
Table 1: Age-dependent lower limits of normal for hemoglobin and iron status parameters [10, 36].
Age (years) Hb (g/dL) Age (years) Serum iron (µg/dL) TSAT (%) Age (years) Serum ferritin (µg/L)
0.5–6 10.5 0.5–2 16 6 0.5–15 7
7–12 11.0 2–6 20 7 — —
>12 female 12.0 6–12 23 7 >15 female 12
>12 male 14.0 >12 48 18 >15 male 15
Hb: hemoglobin; TSAT: transferrin saturation.
month 4 was almost twofold lower in the IPC group versus
ferrous sulfate (22.7 ± 26.1µg/mL versus 42.5 ± 62.0µg/mL,
P = 0.001).
3.3. Tolerability. Overall, 38.8% patients (40/103) reported
one or more gastrointestinal adverse event typical for oral
iron supplementation, with a signiﬁcantly lower frequency
of events in the IPC group (26.9% [14/52]) compared to
the ferrous sulfate group (50.9% [26/51], P = 0.012)
(Table 3). The frequencies of nausea/abdominal pain and of
constipation were comparable between groups, but 25.4% of
patients receiving ferrous sulfate experienced both types of
adverse events compared to 1.9% of IPC-treated patients. No
cases of diarrhea were reported during the study period.
3.4. Acceptability. Treatment acceptability at day 7 was com-
parable for both groups, but at months 1 and 4, the children
found it signiﬁcantly easier to accept IPC administration
than ferrous sulfate (Figure 1). At the end of the four-month
study period, the mean facial expression score on the ﬁve-
point Wong-Baker scale was 0.51 points lower in the IPC
group compared to the ferrous sulfate group (1.63 ± 0.56
versus 2.14 ± 0.75, P = 0.001).
4. Discussion
Results from this large, randomized study show that
improvements in hematologic parameters and the availabil-
ity of iron for erythropoiesis are comparable with IPC and
f e r r o u ss u l f a t eo v e raf o u r - m o n t hp e r i o di nc h i l d r e nw i t h
IDAbutareachievedwithfeweradverseeventsandimproved
acceptability using IPC.
A number of studies have previously demonstrated that
IPC achieves a signiﬁcant increase in Hb levels in children
with IDA [11, 12, 16–18]. The rate of the erythropoietic
response to IPC appears to be dose dependent. In a study
of 63 adults with IDA, the mean time to achieve target
Hb level was 6.6, 8.3, and 11.3 weeks, respectively, for
patients receiving 200, 400, or 600mg iron [19]. At a dose
of 200mg iron/day, Langstaﬀ et al. observed Hb increases
to be higher with ferrous sulfate than IPC at weeks 3 and
6, but not at week 9 [20]. Similarly, Murahovschi et al.
found in a randomized trial of 49 IDA infants that patients
treated with ferrous sulfate showed a faster increase in Hb
during the ﬁrst month of treatment compared to those given
IPC at a dose of 4mg/kg/day, but that the increase was
then slower with ferrous sulfate [12]. This may explain the
lack of response to IPC 100–300mg/day after one month
IPC (n = 52)
Ferrous sulfate (n = 51)
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Figure 1: Acceptability score in pediatric patients with iron deﬁ-
ciency anemia receiving oral iron therapy in the form of iron
hydroxide polymaltose complex (IPC) or ferrous sulfate. Accept-
ability was assessed using the Wong-Baker scale [15], on which a
“happy face” (score 0) stands for no diﬃculties, while a “sad face”
(score 5) indicates that the child refused or was forced to take the
medicine.
described in a small study of 16 iron-depleted adults [21].
It has been suggested that the bioavailability of iron may
be lower to IPC than iron salts [21, 22], but evaluation of
iron bioavailability from orally administered compounds is
complex, and conventional pharmacokinetic measurements
of serum iron concentration are largely irrelevant in this
setting[23,24].Thetruemeasurementofironbioavailability
is uptake of iron into the erythrocytes, which peaks at 2-
3 weeks after the start of oral iron administration, and
which is similar with IPC and ferrous salts including ferrous
sulfate [9, 25]. In our population, the equivalent reticulocyte
responseatday7suggeststhatIPCrapidlyprovidesadequate
iron bioavailability for eﬀective erythropoiesis. By month 1,
there was a signiﬁcant increase in Hb in the IPC cohort
compared to baseline and no signiﬁcant diﬀerence was seen
between the IPC and ferrous sulfate arm. Of the other
ﬁve hematologic parameters that were measured, only MCV
showed a signiﬁcantly greater improvement in the ferrous
sulfate arm at month 1. At month 4, although absolute Hb
was lower in the IPC arm, the change in Hb from baseline
was similar between treatment groups. While levels of the4 International Journal of Pediatrics
Table 2:Baselinevaluesandchangesinerythrocyte-relatedhematologicandironstatusparametersinpediatricpatientswithirondeﬁciency
anemia receiving oral iron therapy with iron hydroxide polymaltose complex (IPC) or ferrous sulfate.
IPC (n = 52) Ferrous sulfate (n = 51) P value IPC versus ferrous sulfate
Value
Change
from
baseline
P valuea Value
Change
from
baseline
P valuea Absolute value
Change
from
baseline
Hb (g/dL)
Baseline 9.5 ± 1.10 — — 9.4 ± 1.6 — — 0.849 —
1 month 10.6 ± 1.0 1.2 ± 0.9 0.001 11.2 ± 0.9 1.8 ± 1.7 0.001 0.002 0.060
4 months 11.7 ± 0.8 2.3 ± 1.3 0.001 12.4 ± 1.0 3.0 ± 2.3 0.001 0.001 0.349
Hct (%)
Baseline 29.4 ± 2.7 — — 29.5 ± 4.2 — — 0.954 —
1 month 32.7 ± 2.2 3.2 ± 2.3 0.001 34.4 ± 2.8 4.9 ± 4.8 0.001 0.001 0.191
4 months 35.5 ± 2.5 6.0 ± 3.3 0.001 37.5 ± 3.2 8.0 ± 6.1 0.001 0.001 0.311
MCV (fL)
Baseline 68.7 ± 7.9 — — 68.4 ± 8.0 — — 0.835 —
1 month 71.7 ± 6.8 3.0 ± 3.2 0.001 74.0 ± 5.8 5.7 ± 6.5 0.001 0.061 0.012
4 months 76.3 ± 5.3 7.5 ± 6.7 0.001 79.5 ± 5.8 11.1 ± 8.2 0.001 0.004 0.013
MCH (pg)
Baseline 22.3 ± 3.6 — — 21.9 ± 3.7 — — 0.565 —
1 month 23.4 ± 3.1 1.1 ± 1.5 0.001 24.0 ± 2.7 2.1 ± 2.9 0.001 0.276 0.050
4 months 25.2 ± 2.3 2.8 ± 2.7 0.001 26.1 ± 2.6 4.2 ± 3.7 0.001 0.050 0.050
MCHC (%)
Baseline 31.7 ± 1.7 — — 31.4 ± 2.2 — — 0.467 —
1 month 32.5 ± 1.4 0.8 ± 1.0 0.001 32.3 ± 1.6 0.9 ± 1.4 0.001 0.446 0.611
4 months 33.5 ± 0.8 1.7 ± 1.4 0.001 33.2 ± 1.2 1.7 ± 1.8 0.001 0.129 0.731
RBC count (×1012/L)
Baseline 4.3 ± 0.4 — — 4.2 ± 0.5 — — 0.705 —
1m o n t h 4 . 5± 0.4 0.2 ± 0.3 0.001 4.6 ± 0.4 0.3 ± 0.4 0.001 0.551 0.675
4m o n t h s 4 . 8± 0.4 0.5 ± 0.3 0.001 4.8 ± 0.4 0.6 ± 0.5 0.001 0.550 0.882
TSAT (%)
Baseline 5.1 ± 3.3 — — 5.4 ± 3.5 — — 0.864 —
4 months 20.2 ± 15.5 15.2 ± 14.9 0.001 22.4 ± 13.2 17.2 ± 13.3 0.001 0.140 0.284
Serum ferritin (µg/L)
Baseline 10.7 ± 8.5 — — 7.8 ± 7.6 — — 0.007 —
4 months 33.4 ± 31.6 22.7 ± 26.1 0.001 50.3 ± 67.3 42.5 ± 62.0 0.001 0.006 0.001
S e r u mi r o n( µg/dL)
Baseline 22.2 ± 13.4 — — 23.2 ± 13.9 — — 0.746 —
4 months 76.3 ± 60.5 54.2 ± 58.2 0.001 75.7 ± 36.8 52.5 ± 37.7 0.001 0.210 0.432
SIBC (µg/dL)
Baseline 452 ± 68 — — 447 ± 78 — — 0.710 —
4 months 379 ± 46 −73 ± 54 0.001 354 ± 52 −93 ± 77 0.001 0.011 0.259
aP value for change from baseline.
Data shown as mean ± SD.
Hb:hemoglobin;Hct:hematocrit;IPC:ironhydroxidepolymaltosecomplex;MCH:meancorpuscularhemoglobin;MCV:meancorpuscularvolume;MCHC:
mean corpuscular hemoglobin concentration; RBC: red blood cell; SIBC: serum iron binding capacity; TSAT: transferrin saturation.
storage iron ferritin were higher with ferrous sulfate, TSAT
exceeded 20% in both groups, indicating that adequate iron
was available for erythropoiesis.
A drawback of oral iron supplementation, particularly
ferrous sulfate, is the high incidence of gastrointestinal
adverse events such as nausea, vomiting, abdominal cramps,
constipation and diarrhea, and tooth staining [7, 26].
Randomized studies in adults have conﬁrmed a lower rate of
gastrointestinal symptoms with IPC versus ferrous sulfate
[8,20,27,28].Inchildren,comparativedataaremoresparse,International Journal of Pediatrics 5
Table 3: Adverse events in pediatric patients with iron deﬁciency
anemia receiving oral iron therapy with iron hydroxide polymaltose
complex (IPC) or ferrous sulfate, n (%).
IPC Ferrous sulfate P value
(n = 52) (n = 51)
Nausea or abdominal pain 9 (17.3) 9 (17.6) —
Constipation 4 (7.6) 4 (7.8) —
Nausea or abdominal pain
plus constipation
1 (1.9) 13 (25.4) —
Total 14 (26.9) 26 (50.9) 0.012
but there are reports of fewer gastrointestinal adverse events
[12] and less frequent tooth staining [11] in IPC-treated
children compared to those given ferrous sulfate. The
diﬀerences in safety proﬁles between the two preparations
are attributed to a slower release of iron from the stable
IPC complex [9]. Rapid iron release from ferrous sulfate
within the gastric lumen can overload the active, control
uptake mechanism in the enterocytes, leading to local gut
reactions and symptoms such as vomiting and dyspepsia.
Overload of the active uptake mechanism also leads to
passive absorption via the intercellular route and absorption
of iron from the gut directly into the bloodstream [29],
with a consequent increase in nontransferrin bound iron
(NTBI). NTBI iron is known to induce oxidative stress that
can cause systemic adverse events including nausea. The
rise in NTBI thus is negligible after IPC dosing since the
size of the hydroxide complex means that there is almost
no passive diﬀusion and the slow release of iron avoids
overload of the active transport mechanism [9], but when
iron is given in the form of ferrous salts, rapid release of
ironmeans thatthere is adose-dependent passive absorption
of iron [29]. As a consequence, ferrous sulfate is associated
with increased levels of NTBI and increased oxidative stress
[28–30], whereas IPC administration is not [28, 29]. The
signiﬁcantly lower rate of gastrointestinal adverse events
seen with IPC compared to ferrous sulfate in the current
study is in line with earlier clinical experience in children
[12] and with the diﬀerence in iron absorption patterns.
Taking ferrous salts at mealtimes improves gastrointestinal
tolerance, but markedly reduces iron bioavailability such
that it is recommended to take ferrous sulfate between
meals. IPC, in contrast, can be taken at meal times without
compromising bioavailability [31]o re ﬀectiveness [18]. The
good tolerability of IPC was conﬁrmed in a randomized
trial of IPC versus ferrous gluconate in a series of 105
healthy infants to assess their eﬃcacy in the prevention of
anemia [32]. Adverse eﬀects such as vomiting, diarrhea,
constipation, and discolored teeth were signiﬁcantly less
frequent in the IPC treatment group, although mean Hb
levels were higher in the ferrous gluconate arm.
The progressive increase in erythrocyte-related hema-
tologic parameters between months 1 and 4 conﬁrms the
beneﬁt of a long-term treatment schedule in patients given
oral iron supplementation. Compliance is inevitably an issue
for any long-term treatment regimen, but the high rate
of gastrointestinal adverse events in infants and children
given ferrous sulfate [12, 33] is likely to be an additional
barrier. Limited data from studies in children and infants
havesuggestedthatcompliance[34]andadherence[35]with
a ferrous sulfate regimen may be as low as 30–40% over
a one-week period. Two randomized studies in pregnant
womenhaveshownsigniﬁcantlyhighercompliancewithIPC
than ferrous sulfate [36, 37], but comparative data are not
available in children. Our evaluation of the acceptability of
IPC versus ferrous sulfate showed a progressive increase in
theunfavorableattitudeoftheinfantsandchildrentoferrous
sulfate compared to IPC over the four-month study period,
which would tend to discourage compliance.
In conclusion, the results of this study show that IPC
is as eﬀective as ferrous sulfate when used as an oral iron
replacement therapy in pediatric patients with iron deﬁ-
ciency anemia. The superior tolerability of IPC compared to
ferrous sulfate translated into better treatment acceptability
in this population of infants and children.
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